The aim of the present study was to investigate brain glucose metabolism in patients with Hodgkin disease (HD) after diagnosis and during chemotherapy treatment. Following the administration of first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy, 74 HD patients underwent (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography (PET)/computed tomography brain scans, both baseline (PET0) and interim (PET2) at the Department of Biomedicine and Prevention, University of Rome Tor Vergata (Rome, Italy). Fifty-seven patients were further evaluated 15±6 days after four additional cycles (PET6). Furthermore, a control group (CG) of 40 chemotherapy-naïve subjects was enrolled. Differences in brain (18)F-FDG uptake between the CG, PET0, PET2 and PET6 scans were analyzed using statistical parametric mapping. Compared with the PET0 and CG scans, the PET2 scan demonstrated a higher metabolic activity in Brodmann area (BA) 39, and a metabolic reduction in BA 11 bilaterally and in left BA 32. All of these changes disappeared at PET6. The results of the present study indicate that ABVD chemotherapy has a limited impact on brain metabolism.

Chiaravalloti, A., Pagani, M., Cantonetti, M., Di Pietro, B., Tavolozza, M., Travascio, L., et al. (2015). Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study. ONCOLOGY LETTERS, 9(2), 685-690 [10.3892/ol.2014.2765].

Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study

CHIARAVALLOTI, AGOSTINO;CANTONETTI, MARIA;TAVOLOZZA, MARIO;SCHILLACI, ORAZIO
2015-07-01

Abstract

The aim of the present study was to investigate brain glucose metabolism in patients with Hodgkin disease (HD) after diagnosis and during chemotherapy treatment. Following the administration of first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy, 74 HD patients underwent (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography (PET)/computed tomography brain scans, both baseline (PET0) and interim (PET2) at the Department of Biomedicine and Prevention, University of Rome Tor Vergata (Rome, Italy). Fifty-seven patients were further evaluated 15±6 days after four additional cycles (PET6). Furthermore, a control group (CG) of 40 chemotherapy-naïve subjects was enrolled. Differences in brain (18)F-FDG uptake between the CG, PET0, PET2 and PET6 scans were analyzed using statistical parametric mapping. Compared with the PET0 and CG scans, the PET2 scan demonstrated a higher metabolic activity in Brodmann area (BA) 39, and a metabolic reduction in BA 11 bilaterally and in left BA 32. All of these changes disappeared at PET6. The results of the present study indicate that ABVD chemotherapy has a limited impact on brain metabolism.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/36 - Diagnostica per Immagini e Radioterapia
English
Con Impact Factor ISI
Hodgkin disease; adriamycin; bleomycin; chemobrain; chemotherapy; positron emission tomography; vinblastine and dacarbazine
https://www.spandidos-publications.com/10.3892/ol.2014.2765
Chiaravalloti, A., Pagani, M., Cantonetti, M., Di Pietro, B., Tavolozza, M., Travascio, L., et al. (2015). Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study. ONCOLOGY LETTERS, 9(2), 685-690 [10.3892/ol.2014.2765].
Chiaravalloti, A; Pagani, M; Cantonetti, M; Di Pietro, B; Tavolozza, M; Travascio, L; Di Biagio, D; Danieli, R; Schillaci, O
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Brain metabolic changes in Hodgkin.pdf

accesso solo dalla rete interna

Licenza: Copyright dell'editore
Dimensione 684.24 kB
Formato Adobe PDF
684.24 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/119053
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 12
social impact